MBX Biosciences, Inc.
MBX
Positions held
Your positionsMBX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- MBX Biosciences is positioned in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and innovations, attracting significant investor interest.
- The company has a market capitalization of approximately $2.74 billion, indicating a strong presence in the market.
- MBX has a target mean price of $94.3, suggesting a substantial upside potential from its current valuation.
- Despite its potential, MBX has reported negative net income for several consecutive quarters, with a net income of -37.095 million in Q2 2026.
- The company has not generated any revenue, reflecting ongoing challenges in its operational performance.
- The current financial score indicates a 'Strong Sell' signal with a score of -19.00, highlighting significant concerns among analysts.
Fundamentals
| Market cap | $2.56B | Enterprise value | $2.15B | Trailing P/E | — | Forward P/E | -13.39 |
| PEG | — | Price / book | 6.23 | Beta | 0.10 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -33.2% | ROA | -22.1% | Debt / equity | 0.01 |
| Current ratio | 18.08 | Free cash flow | -$53.01M | Analyst recommendation | strong_buy | Mean target | $94.30 |
| 52w high | $72.64 | 52w low | $12.94 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$37.1M | -$23.5M | -$22.1M | -$21.6M | -$19.4M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$40.9M | -$27.3M | -$25.8M | -$23.9M | -$21.8M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$87.0M | -$61.9M | -$32.6M | -$26.1M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$98.1M | -$68.2M | -$35.3M | -$25.2M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-09 · MBX Biosciences to Participate in Upcoming Investor Conferences
2026-09-08 · MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
2026-08-14 · UMH Properties and 4 More Stocks See Action From Activist Investors
2026-08-10 · Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating
2026-08-06 · MBX Biosciences Shares Lower After Q2 Loss Widens
2026-08-06 · MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-07-15 · Attovia Therapeutics Appoints John W. Smither to Board of Directors
2026-07-13 · MBX Biosciences Appoints Steve Hoerter as CEO; Kent Hawryluk Steps Down
2026-07-13 · MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
Price (daily)
Full chart · RSI · MACD · patterns